PFE
37
4
DE
49
3
DHI
36
3
MO
47
6
BAC
38
3
BLK
46
2
DG
14
6
SWK
53
4
PLD
35
5
F
38
4
HSIC
42
2
FCX
44
4
PNR
56
2
UAL
73
3
VRSN
59
4
JNPR
59
3
BMY
40
-5
CHRW
53
2
LEN
21
3
NWSA
69
4
PFE
37
4
DE
49
3
DHI
36
3
MO
47
6
BAC
38
3
BLK
46
2
DG
14
6
SWK
53
4
PLD
35
5
F
38
4
HSIC
42
2
FCX
44
4
PNR
56
2
UAL
73
3
VRSN
59
4
JNPR
59
3
BMY
40
-5
CHRW
53
2
LEN
21
3
NWSA
69
4
Financhill
Back

Akero Therapeutics 10K Form

Sell
32

AKRO
Akero Therapeutics

Last Price:
$29.35
Seasonality Move:
-9.11%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AKRO News And Ratings

See the #1 stock for the next 7 days that we like better than AKRO

AKRO Financial Statistics

Sales & Book Value

Annual Sales: --
Cash Flow: $-70.4M
Price / Cash Flow: 0
Annual Sales: $10.61
Price / Book: 2.77

Profitability

EPS (TTM): -3.78000
Net Income (TTM): $-237.2M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Akero Therapeutics Earnings Forecast

Key Akero Therapeutics Financial Ratios

  • The Interest Expense is -2.04% of Operating Income.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

Akero Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AKRO
CUSIP: 00973Y
Website: akerotx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AKRO Technical Analysis vs Fundamental Analysis

Sell
32
Akero Therapeutics (AKRO) is a Sell

Is Akero Therapeutics a Buy or a Sell?